Top

Published in:

01-06-2014 | Topic Paper

Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy

Authors: Dae Y. Kim, Jose A. Karam, Christopher G. Wood

Published in: World Journal of Urology | Issue 3/2014

Abstract

Numerous biological pathways are affected in renal cell carcinoma and the introduction of targeted agents has improved the survival of patients with advanced and metastatic disease. Durable and long-lasting cure is rarely achieved, and in select cases, the excision of metastatic deposits has shown to increase survival. Clinical trials of targeted agents are being explored as neoadjuvant and adjuvant therapies with the role of metastasectomy evolving in the treatment paradigm. This review examines published reports of metastasectomy and its developing role in the era of targeted therapy. A Medline search was conducted using keywords “metastasectomy,” “renal cell carcinoma,” and “targeted therapy,” and selected articles are discussed by examining prognostic stratification and metastasectomy in major anatomic regions. Most published reports span earlier periods of immunotherapy and chemotherapy, and henceforth, discussions are in historical context in this review. Although there is lack of Level 1 evidence, reports have suggested the prognostic value and survival benefit for metastasectomy in lesions that are amenable to complete resection after longer disease-free intervals in carefully selected patients with adequate performance status. Therefore, the role of metastasectomy must be further elucidated in the era of targeted therapy.

Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR (2008) Renal cell cancer stage migration: analysis of the national cancer data base. Cancer 113(1):78–83. doi:10.1002/cncr.23518 PubMedCrossRef

Chen DY, Uzzo RG (2009) Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw: JNCCN 7(6):635–642 quiz 643PubMedCentralPubMed

Russo P (2011) The role of surgery in the management of early-stage renal cancer. Hematol Oncol Clin North Am 25(4):737–752. doi:10.1016/j.hoc.2011.04.009 PubMedCrossRef

Flanigan RC (2004) Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res Off J Am Assoc Cancer Res 10(18 Pt 2):6335S–6341S. doi:10.1158/1078-0432.CCR-sup-040026 CrossRef

Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970PubMedCrossRef

Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O’Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF (1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76(5):824–832PubMedCrossRef

Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316(15):889–897. doi:10.1056/nejm198704093161501 PubMedCrossRef

Vogelzang NJ, Lipton A, Figlin RA (1993) Subcutaneous interleukin-2 plus interferon α-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol: Off J Am Soc Clin Oncol 11(9):1809–1816

Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer: the Cochrane database of systematic reviews (1):CD001425. doi:10.1002/14651858.CD001425.pub2

10.

Kim B, Louie AC (1992) Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 127(11):1343–1349 Chicago Ill: 1960PubMedCrossRef

11.

Krishnamurthi V, Novick AC, Bukowski RM (1998) Efficacy of multimodality therapy in advanced renal cell carcinoma. Urology 51(6):933–937PubMedCrossRef

12.

Breau RH, Blute ML (2010) Surgery for renal cell carcinoma metastases. Curr Opin Urol 20(5):375–381. doi:10.1097/MOU.0b013e32833c7ada PubMedCrossRef

13.

Russo P, O’Brien MF (2008) Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 35(4):679–686. doi:10.1016/j.ucl.2008.07.009 PubMedCrossRef

14.

Staehler M (2011) The role of metastasectomy in metastatic renal cell carcinoma. Nat Rev Urol 8(4):180–181. doi:10.1038/nrurol.2011.30 PubMedCrossRef

15.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 24(1):16–24. doi:10.1200/jco.2005.02.2574 CrossRef

16.

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O’Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 24(16):2505–2512. doi:10.1200/jco.2005.03.6723 CrossRef

17.

Rini BI, Sosman JA, Motzer RJ (2005) Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. BJU Int 96(3):286–290. doi:10.1111/j.1464-410X.2005.05616.x PubMedCrossRef

18.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ (2011) Targeted therapy for advanced renal cell cancer (RCC): a cochrane systematic review of published randomised trials. BJU Int 108(10):1556–1563. doi:10.1111/j.1464-410X.2011.10629.x PubMedCrossRef

19.

Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB (1997) Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol 158(5):1691–1695PubMedCrossRef

20.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 17(8):2530–2540

21.

Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 23(4):832–841. doi:10.1200/JCO.2005.05.179 CrossRef

22.

Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 20(1):289–296CrossRef

23.

Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P (2008) Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 180(3):873–878. doi:10.1016/j.juro.2008.05.006 discussion 878PubMedCentralPubMedCrossRef

24.

Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A (2003) Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 98(12):2566–2575. doi:10.1002/cncr.11851 PubMedCrossRef

25.

Lara PN, Jr., Tangen CM, Conlon SJ, Flanigan RC, Crawford ED, Southwest Oncology Group Trial S (2009) Predictors of survival of advanced renal cell carcinoma: long-term results from southwest oncology group trial S8949. J Urol 181(2):512–516. doi:10.1016/j.juro.2008.10.021 discussion 516–517CrossRef

26.

Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol: Off J Am Soc Clin Oncol 16(6):2261–2266

27.

Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE (2005) Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 48(1):77–81. doi:10.1016/j.eururo.2005.03.004 discussion 81–72PubMedCrossRef

28.

Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882. doi:10.1002/cncr.25836 PubMedCrossRef

29.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol: Off J Am Soc Clin Oncol 27(34):5794–5799. doi:10.1200/JCO.2008.21.4809 CrossRef

30.

Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W, Takahashi M, Terachi T, Ozono S, Naito S, Tomita Y (2013) Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases: a multicenter study of 556 patients. Urology 82(4):846–851. doi:10.1016/j.urology.2013.06.035 PubMedCrossRef

31.

Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I (2006) Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5(3):232–234. doi:10.3816/CGC.2006.n.042 PubMedCrossRef

32.

Thomas AA, Rini BI, Stephenson AJ, Garcia JA, Fergany A, Krishnamurthi V, Novick AC, Gill IS, Klein EA, Zhou M, Campbell SC (2009) Surgical resection of renal cell carcinoma after targeted therapy. J Urol 182(3):881–886. doi:10.1016/j.juro.2009.05.014 PubMedCrossRef

33.

Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM (2011) Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439–444. doi:10.1016/j.juro.2010.09.086 PubMedCrossRef

34.

Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. doi:10.1093/annonc/mdr362 PubMedCrossRef

35.

Weiss L, Harlos JP, Torhorst J, Gunthard B, Hartveit F, Svendsen E, Huang WL, Grundmann E, Eder M, Zwicknagl M et al (1988) Metastatic patterns of renal carcinoma: an analysis of 687 necropsies. J Cancer Res Clin Oncol 114(6):605–612PubMedCrossRef

36.

Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung. J Urol 42:269–276

37.

Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI (1992) Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 54(1):33–38PubMedCrossRef

38.

Murthy SC, Kim K, Rice TW, Rajeswaran J, Bukowski R, DeCamp MM, Blackstone EH (2005) Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg 79(3):996–1003. doi:10.1016/j.athoracsur.2004.08.034 PubMedCrossRef

39.

Cerfolio RJ, Allen MS, Deschamps C, Daly RC, Wallrichs SL, Trastek VF, Pairolero PC (1994) Pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 57(2):339–344PubMedCrossRef

40.

Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74(5):1653–1657PubMedCrossRef

41.

Assouad J, Petkova B, Berna P, Dujon A, Foucault C, Riquet M (2007) Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg 84(4):1114–1120. doi:10.1016/j.athoracsur.2007.04.118 PubMedCrossRef

42.

Assouad J, Riquet M, Berna P, Danel C (2007) Intrapulmonary lymph node metastasis and renal cell carcinoma. Eur J Cardiothorac Surg 31(1):132–134. doi:10.1016/j.ejcts.2006.10.025 PubMedCrossRef

43.

Reinke RT, Higgins CB, Niwayama G, Harris RH, Friedman PJ (1976) Bilateral pulmonary hilar lymphadenopathy: an unusual manifestation of metastatic renal cell carcinoma. Radiology 121(1):49–53. doi:10.1148/121.1.49 PubMedCrossRef

44.

Winter H, Meimarakis G, Angele MK, Hummel M, Staehler M, Hoffmann RT, Hatz RA, Lohe F (2010) Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. J Urol 184(5):1888–1894. doi:10.1016/j.juro.2010.06.096 PubMedCrossRef

45.

Kawashima A, Nakayama M, Oka D, Sato M, Hatano K, Mukai M, Nagahara A, Nakai Y, Takayama H, Inoue M, Shiono H, Nishimura K, Okumura M, Nonomura N (2011) Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience. Int J Clin Oncol 16(6):660–665. doi:10.1007/s10147-011-0244-0 PubMedCrossRef

46.

Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Ruttinger D, Lohe F, Preissler G, Hatz RA, Winter H (2011) Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg 202(2):158–167. doi:10.1016/j.amjsurg.2010.06.029 PubMedCrossRef

47.

McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK (2013) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. doi:10.1016/j.eururo.2013.08.012 PubMed

48.

Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL (2010) Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(4):1185–1192. doi:10.1016/j.ijrobp.2009.03.062 PubMedCrossRef

49.

Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schoffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4):794–800. doi:10.1093/annonc/mdq554 PubMedCrossRef

50.

Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ (2008) Sorafenib for metastatic renal cancer: the princess Margaret experience. Am J Clin Oncol 31(2):182–187. doi:10.1097/COC.0b013e3181574084 PubMedCrossRef

51.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265. doi:10.1002/cncr.25219 PubMedCrossRef

52.

Patil S, Figlin RA, Hutson TE, Michaelson MD, Negrier S, Kim ST, Huang X, Motzer RJ (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22(2):295–300. doi:10.1093/annonc/mdq342 PubMedCrossRef

53.

Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8):1794–1801. doi:10.2106/JBJS.F.00603 PubMedCrossRef

54.

Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, Sylvester R, Group EGTC (2009) Radical nephrectomy with and without lymph-node dissection: final results of European organization for research and treatment of cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55(1):28–34. doi:10.1016/j.eururo.2008.09.052 CrossRef

55.

Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H (2011) Lymph node dissection in renal cell carcinoma. Eur Urol 60(6):1212–1220. doi:10.1016/j.eururo.2011.09.003 PubMedCrossRef

56.

Boorjian SA, Crispen PL, Lohse CM, Leibovich BC, Blute ML (2008) Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy. J Urol 180(1):99–103. doi:10.1016/j.juro.2008.03.025 PubMedCrossRef

57.

Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D (2006) Outcome following hepatic resection of metastatic renal tumors: the Paul brousse hospital experience. HPB 8(2):100–105. doi:10.1080/13651820500496266 PubMedCentralPubMedCrossRef

58.

Hatzaras I, Gleisner AL, Pulitano C, Sandroussi C, Hirose K, Hyder O, Wolfgang CL, Aldrighetti L, Crawford M, Choti MA, Pawlik TM (2012) A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB 14(8):532–538. doi:10.1111/j.1477-2574.2012.00495.x PubMedCentralPubMedCrossRef

59.

Ruys AT, Tanis PJ, Iris ND, van Duijvendijk P, Verhoef C, Porte RJ, van Gulik TM (2011) Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 18(7):1932–1938. doi:10.1245/s10434-010-1526-x PubMedCentralPubMedCrossRef

60.

Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98(2):342–349. doi:10.3171/jns.2003.98.2.0342 PubMedCrossRef

61.

Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS (2008) Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 113(7):1641–1648. doi:10.1002/cncr.23769 PubMedCrossRef

62.

Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53(2):376–381. doi:10.1016/j.eururo.2007.08.053 PubMedCrossRef

63.

Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP (2007) Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res 27(6C):4255–4257PubMed

64.

Verma J, Jonasch E, Allen P, Tannir N, Mahajan A (2011) Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21):4958–4965. doi:10.1002/cncr.26138 PubMedCrossRef

65.

Soffietti R, Trevisan E, Ruda R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6):679–686. doi:10.1097/CCO.0b013e3283571a1c PubMedCrossRef

66.

Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, Urbanic JJ, McMullen KP, Shaw EG, Tatter SB, Ellis TL (2012) The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg 116(5):978–983. doi:10.3171/2012.2.JNS111353 PubMedCentralPubMedCrossRef

67.

Tanis PJ, van der Gaag NA, Busch OR, van Gulik TM, Gouma DJ (2009) Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 96(6):579–592. doi:10.1002/bjs.6606 PubMedCrossRef

68.

Chung AY, Tran TB, Brumund KT, Weisman RA, Bouvet M (2012) Metastases to the thyroid: a review of the literature from the last decade. Thyroid 22(3):258–268. doi:10.1089/thy.2010.0154 PubMedCrossRef

69.

Hegerova L, Griebeler ML, Reynolds JP, Henry MR, Gharib H (2013) Metastasis to the thyroid gland: report of a large series from the mayo clinic. Am J Clin Oncol. doi:10.1097/COC.0b013e31829d1d09 PubMed

70.

Antonelli A, Arrighi N, Corti S, Legramanti S, Zanotelli T, Cozzoli A, Cunico SC, Simeone C (2012) Surgical treatment of atypical metastasis from renal cell carcinoma (RCC). BJU Int 110(11 Pt B):E559–E563. doi:10.1111/j.1464-410X.2012.11271.x PubMedCrossRef

71.

Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E, Group EGW (2011) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):Vi25–vi30. doi:10.1093/annonc/mdr372 PubMed

72.

Ismaili N (2011) Treatment of colorectal liver metastases. World J Surg Oncol 9:154. doi:10.1186/1477-7819-9-154 PubMedCentralPubMedCrossRef

73.

Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E (2009) Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456–460. doi:10.1111/j.1464-410X.2009.08490.x PubMedCrossRef

Title: Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy
Authors: Dae Y. Kim
Jose A. Karam
Christopher G. Wood
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 3/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1293-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Prognostic significance of phospho-histone H3 in prostate carcinoma

A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results

Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma

Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death

Current controversies and challenges in robotic-assisted, laparoscopic, and open partial nephrectomies

Metallic ureteral stents in malignant ureteral obstruction: short-term results and radiological features predicting stent failure in patients with non-urological malignancies